Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Yeon Soo Kim currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The prosecution is focused under 1 distinct examiner and 1 distinct art unit, indicating a single point of activity for the portfolio. This concentration in 1 distinct art unit suggests that the company's current patent efforts are technically specialized. With 1 pending office action, the company can maintain a targeted approach to its intellectual property development.
The busiest examiner, HOPPE, EMMA RUTH, is assigned 1 busiest examiner pending office action. As the company has only 1 pending office action in total, this examiner is responsible for all current responses required by the patent office. The fact that the busiest examiner pending count is 1 means that HOPPE, EMMA RUTH is the sole examiner currently reviewing the company's applications. Since there are no other distinct examiners or art units involved, the company's prosecution strategy should be tailored specifically to the requirements of this 1 examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOPPE, EMMA RUTH | 1 | 42.1% | +56.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17886778 | EARLY CANCER DIAGNOSIS METHOD AND DIAGNOSTIC KIT USING INTERFERON GAMMA GENE CONCENTRATION MEASUREMENT IN EXOSOMES | HOPPE, EMMA RUTH | 23d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17886778 | EARLY CANCER DIAGNOSIS METHOD AND DIAGNOSTIC KIT USING INTERFERON GAMMA GENE CONCENTRATION MEASUREMENT IN EXOSOMES | HOPPE, EMMA RUTH | 23d |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17886778 | EARLY CANCER DIAGNOSIS METHOD AND DIAGNOSTIC KIT USING INTERFERON GAMMA GENE CONCENTRATION MEASUREMENT IN EXOSOMES | HOPPE, EMMA RUTH | 1683 | §103§112 | Final Rejection | 23d | Pending | Aug 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial